Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas

European Journal of Endocrinology

Volumn 169, Issue 3, 2013, Pages 359-366

  Auriemma, Renata S ^a   Pivonello, Rosario ^a   Perone, Ylenia ^a   Grasso, Ludovica F S ^a   Ferreri, Lucia ^a   Simeoli, Chiara ^a   Iacuaniello, Davide ^a   Gasperi, Maurizio ^a,b   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; PROLACTIN;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PULMONARY VALVE INSUFFICIENCY; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

ADULT; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOPAMINE AGONISTS; DRUG MONITORING; EARLY DIAGNOSIS; ERGOLINES; FEMALE; FOLLOW-UP STUDIES; HEART VALVE DISEASES; HEART VALVES; HUMANS; ITALY; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PREVALENCE; PROLACTINOMA; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84883403996     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0231     Document Type: Article

References (46)

1. Biller BMK, Colao A, Petersenn S, Bonert VS & Boscaro M. Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretoty pituitary adenomas. BMC Endocrine Disorders 2010 10 10. (doi:10.1186/1472-6823-10-10)
2. Gillam MP, Molitch ME, Lombardi G & Colao A. Advances in the treatment of prolactinomas. Endocrine Reviews 2006 27 485-534. (doi:10.1210/er.2005-9998)
3. Nutt JG & Wooten GF. Diagnosis and initial management of Parkinson's disease. New England Journal of Medicine 2005 353 1021-1027. (doi:10.1056/NEJMcp043908)
4. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L & Van Zandijcke M. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004 363 1179-1183. (doi:10.1016/S0140-6736(04)15945-X)
5. Schade R, Andersohn F, Suissa S, Haverkamp W & Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine 2007 356 29-38. (doi:10.1056/NEJMoa062222)
6. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S & Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine 2007 356 39-46. (doi:10.1056/NEJMoa054830)
7. Valassi E, Klibanski A & Biller BMK. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism 2010 95 1025-1033. (doi:10.1210/jc.2009-2095)
8. Kars M, Pereira AM, Bax JJ & Romijn JA. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. European Journal of Endocrinology 2008 159 363-367. (doi:10.1530/EJE-08-0611)
9. March 29, 2007 FDA Public Health Advisory: pergolide. Available on: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051192.htm (accessed 26th October 2012).
10. Andersohn F & Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Movement Disorders 2009 24 129-133. (doi:10.1002/mds. 22385)
11. Mokhles MM, Trifiro G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, Mazzaglia G, Herings R, Luise Cd, Ross D et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. Pharmacological Research 2012 65 358-364. (doi:10.1016/j.phrs.2011.11.009)
12. Trifiro G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, Herings R, de Luise C, Ross D, Brusselle G et al. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Safety 2012 35 159-171. (doi:10.2165/11594940-000000000-00000)
13. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G & Lombardi G. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. Journal of Clinical Endocrinology and Metabolism 2008 93 3777-3784. (doi:10.1210/jc.2007-1403)
14. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A & Martino E. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinemia. International Journal of Clinical Practice 2008 62 1864-1869. (doi:10.1111/j.1742-1241.2008.01779.x)
15. Devin JK, Lakhani VT, Byrd BF III & Blevins LS Jr. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocrine Practice 2008 14 672-677. (doi:10.4158/EP.14. 6.672)
16. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A & Atkin SL. Low dose of cabergoline for hyperprolactinemia is not associated with clinically significant valvular heart disease. European Journal of Endocrinology 2008 159 R11-R14. (doi:10.1530/EJE-08-0365)
17. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ & Pereira AM. Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinomas. Journal of Clinical Endocrinology and Metabolism 2008 93 3348-3356. (doi:10.1210/jc.2007-2658)
18. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L & Beckers A. Cabergoline and the risk of valvular lesions in endocrine disease. European Journal of Endocrinology 2008 159 1-5. (doi:10.1530/EJE-08-0213)
19. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009 12 153-157. (doi:10.1007/s11102-008-0134-2)
20. Herring N, Szmigielski C, Becher H, Karavitaki N & Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinomas. Clinical Endocrinology 2009 70 104-108. (doi:10.1111/j.1365-2265.2008.03458.x)
21. Nachtigall L, Valassi E, Lo J, Mc Carty D, Passeri J, Utz A, Biller BMK, Miller KK & Klibanski A. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clinical Endocrinology 2009 72 53-58. (doi:10.1111/j.1365-2265.2009.03608.x)
22. Tan T, Cabrita IZ, Hensman D, Grogono J, Dhillo WS, Baynes KC, Eliahoo J, Meeran K, Robinson S, Nihoyannopoulos P et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clinical Endocrinology 2010 73 369-374. (doi:10.1111/j.1365-2265. 2010.03827.x)
23. Delgado V, Biermasz NR, van Thiel SW, Ewe SH, Marsan NA, Holman ER, Feelders RA, Smit JW, Bax JJ & Pereira AM. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clinical Endocrinology 2012 77 99-105. (doi:10.1111/j.1365-2265.2011.04326.x)
24. Halperin I, Aller J, Varela C, Mora M, Abad A, Doltra A, Santos AE, Batista E, Garcia-Pavia P, Sitges M et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinomas. Clinical Endocrinology 2012 77 275-280. (doi:10.1111/j.1365-2265.2012.04349.x)
25. Elenkova A, Shabani R, Kalinov K & Zacharieva S. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. European Journal of Endocrinology 2012 167 17-25. (doi:10.1530/EJE-12-0121)
26. Cordoba-Soriano JG, Lamas-Oliveira C, Hidalgo-Olivares VM, Tercero-Mart?nez A, Barambio-Ru?z M & Salas-Nieto J. Valvular heart disease in hyperprolactinemic patients treated with low doses of cabergoline. Revista Espanola de Cardiolog?a 2013 66 410-412.
27. Boguszewski CL, dos Santos CM, Sakamoto KS, Marini LC, de Souza AM & Azevedo M. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary 2012 15 44-49. (doi:10.1007/s11102-011-0339-7)
28. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA & Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography . Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Journal of the American Society of Echocardiography 2002 15 167-184. (doi:10.1067/mje.2002.120202)
29. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H et al. Recommendations for evaluation of the severity of native valve regurgitation with two-dimensional and Doppler echocardiography. Journal of the American Society of Echocardiography 2003 16 777-802. (doi:10.1016/S0894-7317(03) 00335-3)
30. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J et al. Recommendations for chamber quantification. European Journal of Echocardiography 2006 7 79-108. (doi:10.1016/j.euje.2005. 12.014)
31. Authors/Task Force Members, Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. European Heart Journal 2007 28 230-268. (doi:10.1093/eurheartj/ehl428)
32. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Hypertension 2003 42 1206-1252. (doi:10.1161/01.HYP.0000107251.49515.c2)
33. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. Journal of Clinical Endocrinology and Metabolism 1997 82 3574-3579. (doi:10.1210/jc.82.11. 3574)
34. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in na?ve than in patients pre-treated with other dopamine agonists: a prospective study in 110 patients. Journal of Clinical Endocrinology and Metabolism 2000 85 2247-2252. (doi:10.1210/jc.85.6. 2247)
35. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G & Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy. Journal of Clinical Endocrinology and Metabolism 2001 86 5256-5261. (doi:10.1210/jc.86.11.5256)
36. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B & Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. European Journal of Endocrinology 2003 148 325-331. (doi:10.1530/eje.0.1480325)
37. Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G & Colao A. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology 2000 53 53-60. (doi:10.1046/j.1365-2265.2000.01016.x)
38. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L & Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Journal of Clinical Endocrinology and Metabolism 1997 82 876-883. (doi:10.1210/jc.82.3.876)
39. Gu H, Luck S, Carroll PV, Powrie J & Chambers J. Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? Clinical Endocrinology 2011 74 608-610. (doi:10.1111/j.1365-2265.2010.03973.x)
40. Popescu BA, Andrade MJ, Badano LP, Fox KF, Flachskampf FA, Lancellotti P, Varga A, Sicari R, Evangelista A, Nihoyannopoulos P et al. European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography. European Journal of Echocardiography 2009 10 893-905. (doi:10.1093/ejechocard/jep151)
41. Sahn DJ, De Maria A, Kisslo J & Weyman A. Recommendations regarding quantitation of M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978 58 1072-1083. (doi:10.1161/01.CIR.58.6.1072)
42. Pepi M, Tamborini G, Galli C, Barbier P, Doria E, Berti M, Guazzi M & Fiorentini C. A new formula for echo-Doppler estimation of right ventricular systolic pressure. Journal of the American Society of Echocardiography 1994 7 20-26.
43. Redfield MM, Nicholson WJ, Edwards WD & Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Annals of Internal Medicine 1992 117 50-52. (doi:10.7326/0003- 4819-117-1-50)
44. Jahnichen S, Horowski R & Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. European Journal of Pharmacology 2005 513 225-228. (doi:10.1016/j.ejphar.2005.03.010)
45. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B & Benjamin EJ. Prevalence and clinical determinants of mitral, tricuspidal, and aortic regurgitation (the Framingham Heart Study). American Journal of Cardiology 1999 83 897-902. (doi:10.1016/S0002-9149(98)01064-9)
46. Antonini A & PoeweW. Fibrotic heart-valve reactions to dopamineagonists treatment in Parkinson's disease. Lancet Neurology 2007 6 826-829. (doi:10.1016/S1474-4422(07)70218-1)